# Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue

> **NCT06830018** · NA · RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 76 (estimated)

## Conditions studied

- Cancer-related Fatigue， Gastric Cancer，Colorectal Cancer，Nano-crystalline Megestrol Acetate，Megestrol Acetate，First-line Treatment

## Interventions

- **DRUG:** Nano-crystalline Megestrol Acetate Oral Suspension
- **COMBINATION_PRODUCT:** Standard Treatment

## Key facts

- **NCT ID:** NCT06830018
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-23
- **Primary completion:** 2026-01
- **Final completion:** 2026-07
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830018, "Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06830018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*